Obesity Drug Cuts Heavy Drinking 41% in Addiction Study

For the 5% of global deaths linked to alcohol use disorder each year, treatment options have been painfully limited. Now, a landmark Danish study reveals that a widely prescribed obesity medication might offer new hope for those fighting addiction.

Researchers tested semaglutide, the drug sold as Wegovy and Ozempic, in 108 adults dealing with both alcohol use disorder and obesity. Over 26 weeks, participants received either weekly injections of the medication or a placebo, alongside traditional talk therapy sessions.

The results surprised even the researchers. People taking semaglutide reduced their heavy drinking days by 41 percentage points, compared to 26 points in those receiving placebo. That's like going from 17 dangerous drinking days per month to just 10.

But the benefits went deeper. Semaglutide users consumed about 468 grams less alcohol per month than the placebo group and cut their daily drinks by 3.5 units. Blood tests confirmed what participants reported, showing improved liver enzyme levels that signal reduced alcohol damage.

The medication also delivered its known weight loss benefits. Participants lost an average of 11 kilograms, shrank their waist circumference by 12 centimeters, and saw improvements in blood sugar control. Health scores for general wellbeing and psychological health climbed too.

Side effects were mostly mild nausea and digestive discomfort that faded over time. Only five people dropped out due to these issues. The medication appeared safe when combined with behavioral therapy, the current standard approach to treating alcohol addiction.

Scientists believe semaglutide works by affecting brain pathways that control both appetite and reward seeking behavior. Until now, only three medications were approved for alcohol use disorder in treatment seeking patients, leaving doctors and patients with few options when those failed.

Why This Inspires

This isn't just about one drug showing promise. It represents a fundamental shift in how we understand addiction. For decades, alcohol use disorder has been treated primarily through willpower and behavioral change. This study suggests that targeting the same biological systems that regulate eating might also quiet the compulsive need to drink.

The research opens doors for the estimated millions worldwide who struggle with both obesity and alcohol addiction, two conditions that often feed each other in destructive cycles. Instead of treating them separately, doctors might soon address both with a single intervention alongside therapy.

Perhaps most importantly, it offers hope to people who've tried everything else. When current medications fail and talk therapy alone isn't enough, semaglutide could provide the biological reset that makes recovery possible.

The future of addiction treatment just got brighter, one weekly injection at a time.